# West Pharmaceutical Services (WST) financials

West Pharmaceutical Services reported revenue of $3.07 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 6.3% from fiscal 2024. Net income was $494 million and diluted earnings per share $6.79.

In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 30 Sep 2026), revenue was $875 million, up 8.7% from a year earlier.

Source: West Pharmaceutical Services's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 29 Oct 2026. Amounts in USD. Page: https://aapwire.com/stocks/WST. Retrieved 2026-11-16.

## Latest results: Q3 FY2026

West Pharmaceutical Services reported revenue of $875 million, up 8.7% from a year earlier, net income of $214 million and diluted earnings per share of $3.02 against $1.92 for the third quarter of fiscal 2026 (the three months to 30 Sep 2026).

From its quarterly report, filed 29 Oct 2026.

| Measure | Q3 FY2026 | Q3 FY2025 | Change |
| --- | ---: | ---: | ---: |
| Revenue | $874.5M | $804.6M | +8.7% |
| Gross profit | $347.4M | $294.3M | +18.0% |
| Gross margin | 39.7% | 36.6% | +3.1 pts |
| Operating income | $267.4M | $167.6M | +59.5% |
| Operating margin | 30.6% | 20.8% | +9.7 pts |
| Net income | $214.0M | $140.0M | +52.9% |
| Diluted EPS | $3.02 | $1.92 | +57.3% |
| Operating cash flow | $189.5M | $197.2M | −3.9% |
| Capital expenditure | $39.10M | $63.30M | −38.2% |
| Free cash flow | $150.4M | $133.9M | +12.3% |

Page: https://aapwire.com/stocks/WST/earnings

## Annual figures (fiscal years)

| Measure | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $1.51B | $1.60B | $1.72B | $1.84B | $2.15B | $2.83B | $2.89B | $2.95B | $2.89B | $3.07B |
| Revenue growth | +7.8% | +6.0% | +7.4% | +7.1% | +16.7% | +31.9% | +2.0% | +2.2% | −1.9% | +6.3% |
| Gross profit | $501.4M | $512.9M | $545.4M | $605.7M | $767.8M | $1.18B | $1.14B | $1.13B | $998.5M | $1.10B |
| Operating income | $195.2M | $225.8M | $240.3M | $296.6M | $406.9M | $752.3M | $734.0M | $676.0M | $569.9M | $584.9M |
| Net income | $143.6M | $150.7M | $206.9M | $241.7M | $346.2M | $661.8M | $585.9M | $593.4M | $492.7M | $493.7M |
| Diluted EPS | $1.91 | $1.99 | $2.74 | $3.21 | $4.57 | $8.67 | $7.73 | $7.88 | $6.69 | $6.79 |
| Operating cash flow | $219.4M | $263.3M | $288.6M | $367.2M | $472.5M | $584.0M | $724.0M | $776.5M | $653.4M | $754.8M |
| Capital expenditure | $170.2M | $130.8M | $104.7M | $126.4M | $174.4M | $253.4M | $284.6M | $362.0M | $377.0M | $285.9M |
| Free cash flow | $49.20M | $132.5M | $183.9M | $240.8M | $298.1M | $330.6M | $439.4M | $414.5M | $276.4M | $468.9M |
| Gross margin | 33.2% | 32.1% | 31.8% | 32.9% | 35.8% | 41.5% | 39.4% | 38.3% | 34.5% | 35.9% |
| Operating margin | 12.9% | 14.1% | 14.0% | 16.1% | 19.0% | 26.6% | 25.4% | 22.9% | 19.7% | 19.0% |
| Net margin | 9.5% | 9.4% | 12.0% | 13.1% | 16.1% | 23.4% | 20.3% | 20.1% | 17.0% | 16.1% |
| Cash and equivalents | $203.0M | $235.9M | $337.4M | $439.1M | $615.5M | $762.6M | $894.3M | $853.9M | $484.6M | $791.3M |
| Total debt | $228.6M | $197.0M | $196.1M | $329.3M | $325.7M | $325.3M | $317.9M | $309.0M | $302.3M | $321.1M |
| Shareholders' equity | $1.12B | $1.28B | $1.40B | $1.57B | $1.85B | $2.34B | $2.68B | $2.88B | $2.68B | $3.18B |
| Diluted shares | 75.0M | 75.8M | 75.4M | 75.4M | 75.8M | 76.3M | 75.8M | 75.3M | 73.7M | 72.7M |
| Dividends per share | $0.50 | $0.54 | $0.58 | $0.62 | $0.66 | $0.70 | $0.74 | $0.78 | $0.82 | $0.86 |

## Quarterly figures (last eight fiscal quarters)

| Measure | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $748.8M | $698.0M | $766.5M | $804.6M | $805.0M | $844.9M | $872.3M | $874.5M |
| Revenue, year on year | +2.3% | +0.4% | +9.2% | +7.7% | +7.5% | +21.0% | +13.8% | +8.7% |
| Gross margin | 36.5% | 33.2% | 35.7% | 36.6% | 37.8% | 35.1% | 37.7% | 39.7% |
| Operating income | $159.6M | $107.0M | $153.7M | $167.6M | $156.6M | $177.1M | $179.1M | $267.4M |
| Net income | $130.1M | $89.80M | $131.8M | $140.0M | $132.1M | $138.8M | $154.0M | $214.0M |
| Diluted EPS | $1.77 | $1.23 | $1.82 | $1.92 | $1.82 | $1.92 | $2.15 | $3.02 |
| Free cash flow | $85.20M | $58.10M | $101.9M | $133.9M | $175.0M | $47.20M | $80.80M | $150.4M |

## Operating KPIs

| KPI | Latest | Period | Change on a year |
| --- | ---: | --- | --- |
| [Proprietary Products revenue](https://aapwire.com/stocks/WST/kpi/proprietary-products-revenue) | $728.8M | quarter to 30 Sep 2026 | up 12.6% |
| [West Vantage revenue](https://aapwire.com/stocks/WST/kpi/west-vantage-revenue) | $145.7M | quarter to 30 Sep 2026 | down 7.3% |
| [United States revenue](https://aapwire.com/stocks/WST/kpi/united-states-revenue) | $1.3B | fiscal year to 31 Dec 2025 | up 8.0% |
| [Germany revenue](https://aapwire.com/stocks/WST/kpi/germany-revenue) | $380.3M | fiscal year to 31 Dec 2025 | up 2.1% |
| [Ireland revenue](https://aapwire.com/stocks/WST/kpi/ireland-revenue) | $333.3M | fiscal year to 31 Dec 2025 | up 3.1% |
| [FR revenue](https://aapwire.com/stocks/WST/kpi/fr-revenue) | $226.6M | fiscal year to 31 Dec 2025 | down 6.4% |

## Method

Each period is read from the report the company filed and checked against accounting identities; a figure that does not pass is left blank (—), never estimated. Free cash flow is operating cash flow less capital expenditure. Diluted EPS is as the company reported it, adjusted for later stock splits. Research information only, not investment advice.
